Back to search

Democritus University of Thrace (DUTH)

Η συστηματική θεραπευτική αντιμετώπιση του μη εγχειρήσιμου καρκίνου του παγκρέατος

Abstract

dc:description

Aim: To evaluate the efficacy, the toxicity and the clinical benefit of gemcitabine combined with docetaxel, irinotecan or capecitabine in patients with inoperable or metastatic pancreatic cancer. We also assessed the effect of age, sex, primary location of the tumor, presence of liver metastases, stage and the response to therapy, on survival and/or treatment choice. Material and methods: 167 patients with advanced pancreatic cancer (st.II, III, IV) were enrolled. 54 pts received the combination of gemcitabine and docetaxel, 60 pts the combination of gemcitabine and irinotecan and 53 pts the combination of gemcitabine and capecitabine. Gemcitabine was given on days 1 and 8 at dose of 1000mg/m2, docetaxel at a dose 100mg/m2 on day 8, Irinotecan at 300mg/m2 on day 8 and capecitabine at dose 1300mg/m2/d p.os divided into two equal doses on days 1-14. Treatment was repeated every 3 weeks. We evaluated the compliance to treatment, response to treatment, survival and toxicity of the regimens. Parameters such as age, sex, primary location, liver metastases, stage and response to therapy effecting on median survival were also investigated using univariate and multivariate analysis models. Results: 1) Gemcitabine plus Docetaxel: A total of 218 cycles were administered. The median duration of response was 5.6 months, the median time to tumor progression (TTP) was 7.4 months and the median survival 6.5 months. Partial response was documented in 13% of the pts and stable disease in 33%. Pain improvement as a result of treatment was observed in 60% of the pts, weight gain in 33% and improvement in P.S in 33%. 2) Gemcitabine plus Irinotecan: A total of 329 cycles were administered. The median duration of response was 5 months, the TTP was 7 months and the median survival was 7 months. There was 1 complete response (1.7%), partial response in 23.3% and stable disease in 36.7% of the pts documented. Pain improvement was observed in 45% of the pts, weight gain in 19.5% and P.S improvement in 48.9%. 3) Gemcitabine plus Capecitabine: A total of 304 cycles were administered. The median duration of response was 5 months, the TTP was 7 months and the median survival was 7 months. Partial response was documented in 18.9% of the pts and stable disease in 41.5%. Pain improvement was observed in 81% of the pts, weight gain in 36% and P.S improvement in 3%. Conclusions: The results reported hereby are among the best in the literature. The statistical analysis showed that patients with partial response to treatment or disease stabilization have a significantly better survival as compared with non-responders. The presence of liver metastases is a parameter with a strong effect on survival. In summary, the present study demonstrated that gemcitabine-based combination chemotherapy is active and well tolerated. In a patient population with poor prognostic features such as patients with advanced pancreatic cancer they should be encouraged to participate in trials with novel cytotoxic agents, in order to establish new standards in the treatment of this disease.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2005

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Amarantidis, Kyriakos
  • Αμαραντίδης, Κυριάκος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/17587

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Amarantidis, Kyriakos; Αμαραντίδης, Κυριάκος. Η συστηματική θεραπευτική αντιμετώπιση του μη εγχειρήσιμου καρκίνου του παγκρέατος. Democritus University of Thrace (DUTH), 2005. http://hdl.handle.net/10442/hedi/17587